
Releases
ADMA Biologics Faces Class Action Lawsuit Over Alleged Revenue Manipulation
Investors who suffered losses in ADMA Biologics, Inc. face an August 10, 2026, deadline to seek appointment as lead plaintiff in a newly filed class action lawsuit. The litigation centers on allegations that the company engaged in securities fraud and unlawful business practices to inflate its reported financial growth.























